Her2/neu testing in gastric cancer: Evaluating the risk of sampling errors

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 725-733

  Warneke, V S ^a   Behrens, H M ^a,b   Boger C ^a   Becker, T ^a   Lordick, F ^c   Ebert, M P A ^d   Rocken C ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

biopsy; Gastric cancer; Her2 neu; Sampling error

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; PARAFFIN; TRASTUZUMAB;

ARTICLE; BIOPSY TECHNIQUE; CANCER CLASSIFICATION; CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; ESOPHAGOGASTRIC JUNCTION CARCINOMA; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GASTRECTOMY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SAMPLING ERROR; SCORING SYSTEM; STOMACH ADENOCARCINOMA; STOMACH CANCER; TISSUE FIXATION; TISSUE MICROARRAY; TISSUE SECTION; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; ESOPHAGEAL NEOPLASMS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; RISK; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874578954     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds528     Document Type: Article

References (26)

1. Hanahan D, Weinberg RA.; Hallmarks of cancer: the next generation. Cell ;2011; 144: 646-674.
2. Bang YJ, Van CE, Feyereislova A et al..; Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet ;2010; 376: 687-697.
3. Rüschoff J, Dietel M, Baretton G et al..; HER2 diagnostics in gastric cancerguideline validation and development of standardized immunohistochemical testing. Virchows Arch ;2010; 457: 299-307.
4. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-Positive gastric cancer and its impact on survival outcomes a systematic review. Int J Cancer 2012; 130(12): 2845-2856.
5. Bilous M, Osamura RY, Ruschoff J et al..; HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2;010; 41: 304-305.
6. Bozzetti C, Negri FV, Lagrasta CA et al.. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104: 1372-1376.
7. Kimura M, Tsuda H, Morita D et al.. ;Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. Jpn J Clin Oncol ;2005; 35: 324-331.
8. Langer R, Rauser S, Feith M et al.. ;Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol ;2011; 24: 908-916.
9. Abraham SC, Park SJ, Lee JH et al.. ;Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. Mod Pathol ;2003; 16: 786-795.
10. Kim MA, Lee HJ, Yang HK et al.. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59: 822-831.
11. Lee S, de Boer WB, Fermoyle S et al.. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 2011; 59: 832-840.
12. Tafe LJ, Janjigian YY, Zaidinski M et al.. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 2011; 135: 1460-1465.
13. Yan B, Yau EX, Bte Omar SS et al.. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010; 63: 839-842.
14. Yan B, Yau EX, Choo SN et al.. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol 2011; 64: 880-883.
15. Lauren T. ;The two histologic main types of gastric carcinoma: diffuse and socalled intestinal-type carcinoma. Acta Pathol Microbiol Scand ;1965; 64: 31-49.
16. Sobin LH, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours, 7th edition. Wiley-Blackwell: Oxford, 2009.
17. Warneke VS, Behrens HM, Hartmann JT et al.. Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol 2011; 29: 2364-2371.
18. Weichert W, Röske A, Gekeler V et al.. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008; 9: 139-148.
19. Rüschoff J, Hanna W, Bilous M et al..; HER2 testing in gastric cancer: a practical approach. Mod Pathol; 2012; 25: 637-650.
20. Fox SB, Kumarasinghe MP, Armes JE et al.. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol 2012; 36: 577-582.
21. Park YS, Hwang HS, Park HJ et al.. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use. Hum Pathol 2012; 43: 413-422.
22. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009; 135: 1331-1339.
23. Ajani JA, Barthel JS, Bekaii-Saab T et al.. Gastric cancer. J Natl Compr Canc Netw 2010; 8: 378-409.
24. Moehler M, Al-Batran SE, Andus T et al.. German S3-guideline 'Diagnosis and treatment of esophagogastric cancer'. Z Gastroenterol 2011; 49: 461-531.
25. Yano T, Doi T, Ohtsu A et al.. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: 65-71.
26. Kim KC, Koh YW, Chang HM et al.. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011; 18: 2833-2840.